Dyadic Strengthens Scientific Advisory Board; Arnold Demain, Ph.D., Carlos Barbas, III, Ph.D., and Joseph Villafranca, Ph.D. to
11 October 2005 - 10:01PM
Business Wire
Dyadic International, Inc. (AMEX:DIL), a biotechnology company
engaged in the development, manufacture and sale of biological
products, today announced changes to its Scientific Advisory Board
(SAB). Joining Dyadic's SAB are Arnold Demain, Ph.D., Professor of
Industrial Microbiology, Emeritus, Massachusetts Institute of
Technology, Carlos Barbas, III, Ph.D., Kellogg Professor and Chair
of Molecular Biology and Chemistry at The Scripps Research
Institute (TSRI), and Joseph Villafranca, Ph.D., Executive Vice
President, Pharmaceutical Development and Operations, Neose
Technologies, Inc. Leaving Dyadic's SAB are Edward McGuire, Ph.D.,
former Vice President of Research & Development, Neose
Technologies, Inc., and Michael Koslowski, Ph.D., Chief Scientist,
Kreido Laboratories. "The new SAB members fit exceptionally well
into Dyadic's strategy for the future and will help guide the
company to select the best opportunities among the numerous fields
where Dyadic's technologies can be applied," commented Mark
Emalfarb, Dyadic's President and CEO. "We are pleased to welcome
these eminent scientists and look forward to their contributions to
the advancement of Dyadic's C1 Host Technology and
commercialization efforts of new and existing products and
processes." Drs. Demain, Barbas, and Villafranca join other
scientific leaders on Dyadic's SAB, which include chairman Dr.
Richard Lerner, Dr. Gerry Fink, and Drs. Arkady Sinitsyn, Peter
Punt and Cees van den Hondel. "Departing SAB members, Drs. McGuire
and Koslowski played an important role in advancing Dyadic's
science and technology. Their scientific guidance and dedicated
service over the years are greatly appreciated and we wish them
well in their future endeavors," added Mark Emalfarb. Bios for Drs.
Demain, Barbas and Villafranca follow below. For complete bios of
all of Dyadic's SAB's current members, please visit Dyadic's
website at http://www.dyadic-group.com. Arnold Demain, Ph.D. Dr.
Demain has been in the forefront of industrial microbiology and
biotechnology for over four decades and has been involved in the
research and commercialization of a number of fermentation based
pharmaceutical processes. He is currently a Fellow at Drew
University's Charles A. Dana Institute for Scientists Emeriti.
Previously, Dr. Demain was at the Massachusetts Institute of
Technology (MIT) for 32 years, where he most recently served as
Professor of Industrial Microbiology in the Department of Biology.
Before going to MIT, Dr. Demain spent fifteen years at Merck &
Co., where he held various positions in R&D and management
focused on fermentation microbiology. His leadership in the area of
fermentation is evidenced by over 470 publications, 10 books of
which he is coeditor or coauthor, 20 U.S. patents and his election
to the presidency of the Society for Industrial Microbiology in
1990, membership in the National Academy of Sciences in 1994, the
Mexican Academy of Sciences in 1997 and the Hungarian Academy of
Sciences in 2001. Dr. Demain received his Ph.D. in Microbiology
from University of California. Carlos Barbas, Ph.D. Dr. Barbas is a
Professor of The Scripps Research Institute, Departments of
Molecular Biology and Chemistry and The Skaggs Institute for
Chemical Biology. He holds the Janet and W. Keith Kellogg II
endowed Chair in Molecular Biology and Chemistry. Dr. Barbas has
received honours including the Investigator Award from the Cancer
Research Institute, The Scholar Award of the American Foundation
for AIDS Research, and the Presidential Green Chemistry Challenge
Award. He is the author of over 200 scientific articles and is a
named inventor on 32 issued U.S. patents. Key accomplishments in
the area of biotechnology pioneered by Dr. Barbas and his
colleagues include the development of the first human antibody
phage libraries, development of the first synthetic antibodies, the
development of the first artificial transcription factors capable
of regulating endogenous genes, and chemically programmed
antibodies-the CovX core technology. Dr. Barbas received his Ph.D.
in Organic Chemistry from Texas A&M University. Joseph
Villafranca, Ph.D. Dr. Villafranca has served as Executive Vice
President, Pharmaceutical Development and Operations at Neose
Technologies, Inc., since February 2004. He joined Neose in October
2002 as Senior Vice President, Pharmaceutical Development and
Operations. From 1992 to 2002 he held various positions at
Bristol-Myers Squibb, serving most recently as Vice President of
Biologics Strategy and Biopharmaceuticals Operations. Prior to
Bristol-Myers, Dr. Villafranca spent 20 years at Penn State
University, including eight years as the Evan Pugh Professor of
Chemistry. Dr. Villafranca earned a B.S. in Chemistry from the
State University of New York and a Ph.D. in Biochemistry/Chemistry
from Purdue University. He completed his post-doctoral training in
Biophysics at the Institute for Cancer Research in Philadelphia.
About Dyadic Dyadic International, Inc., is engaged in the
development, manufacture and sale of biological products (proteins,
enzymes, peptides and other bio-molecules), as well as the
licensing of its enabling proprietary technology to business
collaborators for the discovery, development and manufacture of
biological products from genes. Dyadic markets its products and
services for applications in the textile, chemical, agricultural,
pulp & paper, pharmaceutical, biotechnology and other
industries, using its proprietary C1 Host Technology and C1
Expression and Screening Systems for the discovery, development and
production of biological products. Cautionary Statement for
Forward-Looking Statements Certain statements contained in this
press release are "forward-looking statements." These
forward-looking statements involve risks and uncertainties that
could cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. For a discussion of these risks and uncertainties,
please see our filings from time to time with the Securities and
Exchange Commission, which are available free of charge on the
SEC's web site at http://www.sec.gov, including our Annual Report
on Form 10-KSB for the year ended December 31, 2004, and our
Quarterly Report for the quarter ended June 30, 2005 on Form
10-QSB. Except as required by law, we expressly disclaim any intent
or obligation to update any forward-looking statements.
Dyadic (AMEX:DIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dyadic (AMEX:DIL)
Historical Stock Chart
From Jul 2023 to Jul 2024